Mettler-Toledo International Inc. (0K10.L)
USD 991.96
(-4.33%)
USD 991.96
(-4.33%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 1.97 Billion USD | 3.51% |
| 2022 | 1.9 Billion USD | 20.73% |
| 2021 | 1.58 Billion USD | 23.1% |
| 2020 | 1.28 Billion USD | 3.95% |
| 2019 | 1.23 Billion USD | 25.41% |
| 2018 | 985.02 Million USD | 2.59% |
| 2017 | 960.17 Million USD | 9.73% |
| 2016 | 875.05 Million USD | 52.15% |
| 2015 | 575.13 Million USD | 71.28% |
| 2014 | 335.79 Million USD | -16.32% |
| 2013 | 401.27 Million USD | 12.93% |
| 2012 | 355.33 Million USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 1.9 Billion USD | 0.79% |
| 2024 Q2 | 1.74 Billion USD | -8.24% |
| 2023 FY | 1.88 Billion USD | -1.04% |
| 2023 Q4 | 1.88 Billion USD | -2.11% |
| 2023 Q1 | 2.01 Billion USD | 5.62% |
| 2023 Q2 | 2.04 Billion USD | 1.47% |
| 2023 Q3 | 1.92 Billion USD | -5.67% |
| 2022 Q1 | 1.76 Billion USD | 11.77% |
| 2022 Q4 | 1.9 Billion USD | 4.56% |
| 2022 FY | 1.9 Billion USD | 20.73% |
| 2022 Q2 | 1.82 Billion USD | 3.09% |
| 2022 Q3 | 1.82 Billion USD | 0.21% |
| 2021 Q3 | 1.63 Billion USD | 2.35% |
| 2021 FY | 1.58 Billion USD | 23.1% |
| 2021 Q1 | 1.56 Billion USD | 15.08% |
| 2021 Q2 | 1.6 Billion USD | 2.62% |
| 2021 Q4 | 1.58 Billion USD | -3.58% |
| 2020 Q3 | 1.17 Billion USD | 1.92% |
| 2020 Q2 | 1.15 Billion USD | -24.17% |
| 2020 Q1 | 1.51 Billion USD | 16.87% |
| 2020 FY | 1.28 Billion USD | 3.95% |
| 2020 Q4 | 1.35 Billion USD | 15.72% |
| 2019 FY | 1.23 Billion USD | 25.41% |
| 2019 Q4 | 1.29 Billion USD | 9.17% |
| 2019 Q3 | 1.18 Billion USD | 3.16% |
| 2019 Q2 | 1.15 Billion USD | 7.75% |
| 2019 Q1 | 1.06 Billion USD | 8.58% |
| 2018 Q2 | 1.02 Billion USD | 4.26% |
| 2018 Q1 | 978.71 Million USD | 1.93% |
| 2018 FY | 985.02 Million USD | 2.59% |
| 2018 Q4 | 985.04 Million USD | -0.39% |
| 2018 Q3 | 988.89 Million USD | -3.09% |
| 2017 Q2 | 947.78 Million USD | 0.38% |
| 2017 Q4 | 960.17 Million USD | -8.61% |
| 2017 FY | 960.17 Million USD | 9.73% |
| 2017 Q1 | 944.21 Million USD | 7.9% |
| 2017 Q3 | 1.05 Billion USD | 10.86% |
| 2016 FY | 875.05 Million USD | 52.15% |
| 2016 Q3 | 826.02 Million USD | 19.15% |
| 2016 Q1 | 681.87 Million USD | 18.56% |
| 2016 Q4 | 875.05 Million USD | 5.94% |
| 2016 Q2 | 693.26 Million USD | 1.67% |
| 2015 Q3 | 601.73 Million USD | -1.03% |
| 2015 FY | 575.13 Million USD | 71.28% |
| 2015 Q4 | 575.13 Million USD | -4.42% |
| 2015 Q2 | 608.01 Million USD | 46.74% |
| 2015 Q1 | 414.34 Million USD | 23.39% |
| 2014 Q1 | 454.28 Million USD | 13.21% |
| 2014 Q2 | 349.76 Million USD | -23.01% |
| 2014 Q3 | 368.53 Million USD | 5.37% |
| 2014 Q4 | 335.79 Million USD | -8.89% |
| 2014 FY | 335.79 Million USD | -16.32% |
| 2013 Q4 | 401.27 Million USD | 2.66% |
| 2013 Q2 | 450.22 Million USD | 4.85% |
| 2013 Q3 | 390.87 Million USD | -13.18% |
| 2013 Q1 | 429.41 Million USD | 20.85% |
| 2013 FY | 401.27 Million USD | 12.93% |
| 2012 FY | 355.33 Million USD | 0.0% |
| 2012 Q4 | 355.33 Million USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| uniQure N.V. | 130.06 Million USD | -1418.894% |
| Agios Pharmaceuticals, Inc. | 56.98 Million USD | -3366.607% |
| Amicus Therapeutics, Inc. | 387.85 Million USD | -409.349% |
| Atara Biotherapeutics, Inc. | 45.69 Million USD | -4223.529% |
| bluebird bio, Inc. | 224.41 Million USD | -780.295% |
| Cara Therapeutics, Inc. | 37.07 Million USD | -5227.948% |
| Imunon, Inc. | 1.13 Million USD | -173301.399% |
| Editas Medicine, Inc. | 24.37 Million USD | -8005.818% |
| IQVIA Holdings Inc. | 12.95 Billion USD | 84.751% |
| Myriad Genetics, Inc. | 130.9 Million USD | -1409.206% |
| Neurocrine Biosciences, Inc. | 258.3 Million USD | -664.828% |
| Supernus Pharmaceuticals, Inc. | 33.19 Million USD | -5851.169% |
| Verastem, Inc. | 40.08 Million USD | -4828.279% |
| Walgreens Boots Alliance, Inc. | 8.04 Billion USD | 75.441% |
| Waters Corporation | 2.3 Billion USD | 14.312% |
| Thermo Fisher Scientific Inc. | 31.3 Billion USD | 93.69% |
| Biogen Inc. | 7.18 Billion USD | 72.517% |
| Nektar Therapeutics | 112.62 Million USD | -1654.095% |
| Perrigo Company plc | 3.63 Billion USD | 45.619% |
| Dynavax Technologies Corporation | 252.41 Million USD | -682.65% |
| Illumina, Inc. | 1.48 Billion USD | -32.676% |
| Corbus Pharmaceuticals Holdings, Inc. | 3.23 Million USD | -60899.54% |
| Iovance Biotherapeutics, Inc. | 1 Million USD | -197455.0% |
| Heron Therapeutics, Inc. | 173.75 Million USD | -1036.988% |
| Unity Biotechnology, Inc. | 23.53 Million USD | -8292.667% |
| BioMarin Pharmaceutical Inc. | 593.09 Million USD | -233.092% |
| Sangamo Therapeutics, Inc. | 33.51 Million USD | -5794.525% |
| Evolus, Inc. | 120.35 Million USD | -1541.381% |
| Adicet Bio, Inc. | 17.7 Million USD | -11059.408% |
| Aclaris Therapeutics, Inc. | 3.07 Million USD | -64166.428% |
| Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | 26.91% |
| Esperion Therapeutics, Inc. | 501.54 Million USD | -293.892% |
| FibroGen, Inc. | 89.69 Million USD | -2102.471% |
| Agilent Technologies, Inc. | 2.73 Billion USD | 27.768% |
| OPKO Health, Inc. | 222.03 Million USD | -789.751% |
| Homology Medicines, Inc. | 43.17 Million USD | -4475.574% |
| Geron Corporation | 35.05 Million USD | -5536.216% |
| Alnylam Pharmaceuticals, Inc. | 2.34 Billion USD | 15.684% |
| Exelixis, Inc. | 189.94 Million USD | -940.07% |
| Viking Therapeutics, Inc. | 936 Thousand USD | -210963.034% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Intellia Therapeutics, Inc. | 96.74 Million USD | -1941.975% |
| Zoetis Inc. | 6.56 Billion USD | 69.903% |
| Axsome Therapeutics, Inc. | 178.07 Million USD | -1009.423% |
| Abeona Therapeutics Inc. | 4.4 Million USD | -44778.464% |
| Vertex Pharmaceuticals Incorporated | 724.7 Million USD | -172.602% |
| Kala Pharmaceuticals, Inc. | 34.19 Million USD | -5678.152% |
| Ionis Pharmaceuticals, Inc. | 1.4 Billion USD | -41.073% |
| Sarepta Therapeutics, Inc. | 1.13 Billion USD | -74.439% |
| Corcept Therapeutics Incorporated | - USD | -Infinity% |
| Halozyme Therapeutics, Inc. | 1.49 Billion USD | -31.769% |
| Blueprint Medicines Corporation | 610.96 Million USD | -223.351% |
| Insmed Incorporated | 1.19 Billion USD | -65.546% |
| TG Therapeutics, Inc. | 100.11 Million USD | -1873.222% |
| Incyte Corporation | 29.16 Million USD | -6674.398% |
| Emergent BioSolutions Inc. | 446.5 Million USD | -342.452% |